Drug: Apresazide

WARNING  This fixed-combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static but must be reevaluated as conditions in each patient warrant.
Hydralazine HCI and hydrochlorothiazide is an antihypertensive-diuretic combination available as capsules for oral administration. Hydralazine HCI and hydrochlorothiazide capsules of 25 mg /25 mg contain 25 mg of hydralazine hydrochloride USP and 25 mg of hydrochlorothiazide USP; capsules of 50 mg /50 mg contain 50 mg of hydralazine hydrochloride USP and 50 mg of hydrochlorothiazide USP; and capsules of 100 mg /50 mg contain 100 mg of hydralazine hydrochloride USP and 50 mg of hydrochlorothiazide USP. Each tablet also contains the following inactive ingredients: Corn starch, crospovidone, gelatin, lactose monohydrate, pharmaceutical glaze, sodium starch glycolate, stearic acid, talc, and titanium dioxide. In addition, the 25 mg/25 mg capsule contains ammonium hydroxide, ethylene glycol monoethyl ether, propylene glycol and synthetic black iron oxide; the 50 mg/50 mg capsule contains FD&C Blue #1, FD&C Red #40, FD&C Yellow #6, synthetic red iron oxide and pharmaceutical shellac; and the 100 mg/50 mg capsule contains D&C Red #28, D&C Yellow #10, FD&C Blue #1, FD&C Blue #2, FD&C Red #40, propylene glycol and synthetic black iron oxide. Hydralazine hydrochloride is 1 hydrazinophthalazine monohydrochloride. Hydralazine hydrochloride USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275° C with decomposition, and has a molecular weight of 196.64. Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H -1,2.4-benzothiadiazine-7-sulfonamide 1 ,1 -dioxide. Chemical structure is as follows:

Source: http://www.rxlist.com

Adverse reactions are usually reversible upon reduction of dosage or discontinuation of hydralazine HCI and hydrochlorothiazide. Whenever adverse reactions are moderate or severe, it may be necessary to discontinue the drug. Hydralazine The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency. Common Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. Less Frequent Digestive: Constipation, paralytic ileus. Cardiovascular: Hypotension, paradoxical pressor response, and edema. Respiratory: Dyspnea. Neurologic: Peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety. Genitourinary: Difficulty in urination. Hematologic: Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura, lymphadenopathy, splenomegaly. Hypersensitive Reactions: Rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis. Other: Nasal congestion, flushing, lacrimation, and conjunctivitis. Hydrochlorothiazide The following adverse reactions have been observed but there has not been enough systematic collection of data to support an estimate of their frequency. Consequently the reactions are categorized by organ systems and are listed in decreasing order of severity and not frequency. Digestive: Pancreatitis, jaundice (intrahepatic cholestatic), sialadenitis, vomiting, diarrhea, cramping, nausea, gastric irritation, constipation, anorexia. Cardiovascular: Orthostatic hypotension (may be potentiated by alcohol, barbiturates, or narcotics). Neurologic: Vertigo, dizziness, transient blurred vision, headache, paresthesia, xanthopsia, weakness, and restlessness. Musculoskeletal: Muscle spasm. Hematologic: Aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Metabolic: Hyperglycemia, glycosuria, and hyperuricemia. Hypersensitive Reactions: Necrotizing angitis, Stevens-Johnson syndrome, respiratory distress including pneumonitis and pulmonary edema, purpura, urticaria, rash, photosensitivity. Read the Apresazide (hydralazine and hydrochlorothiazide) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

Dosage should be determined by individual titration (see boxed WARNING). The usual dosage is one hydralazine HCl and hydrochlorothiazide capsule twice daily, the strength depending upon individual requirement following titration. For maintenance, the dosage should be adjusted to the lowest effective level. When necessary, other antihypertensive agents such as sympathetic inhibitors may be added gradually in reduced dosages, and the effects should be watched carefully.

Source: http://www.rxlist.com

Hydralazine MAO inhibitors should be used with caution in patients receiving hydralazine. When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injections and hydralazine are used concomitantly. Hydrochlorothiazide Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may develop during concomitant use of steroids or ACTH. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Thiazides may decrease arterial responsiveness to norepinephrine, but not enough to preclude effectiveness of the pressor agent for therapeutic use. Thiazides may increase the responsiveness to tubocurarine. Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. There have been rare reports in the literature of hemolytic anemia occurring with the concomitant use of hydrochlorothiazide and methyldopa. Concurrent administration of some nonsteroidal anti-inflammatory agents may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics. Drug/Laboratory Test Interactions Thiazides may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. Hydralazine HCI and hydrochlorothiazide should be discontinued before tests for parathyroid function are made (See General, Hydrochlorothiazide, Calcium excretion).Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Hypertension (see boxed WARNING).

Source: http://www.rxlist.com

Hydralazine Hypersensitivity to hydralazine: coronary artery disease; mitral valvular rheumatic heart disease. Hydrochlorothiazide Anuria: hypersensitivity to this or other sulfonamide-derived drugs. Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Acute Toxicity Oral LD50' s in rats (mg/kg): hydralazine, 173 and 187; hydrochlorothiazide, 2750. Signs and Symptoms Hydralazine: Signs and symptoms of overdosage include hypotension, tachycardia, headache, and generalized skin flushing. Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmia and profound shock. Hydrochlorothiazide: The most prominent feature of poisoning is acute loss of fluid and electrolytes. Cardiovascular: Tachycardia, hypotension, and shock. Neuromuscular: Weakness, confusion, dizziness, cramps of the calf muscles, paresthesia, fatigue, impairment of consciousness. Digestive: Nausea, vomiting, thirst. Renal: Polyuria, oliguria or anuria (due to hemoconcentration). Laboratory Findings: Hypokalemia, hyponatremia, hypochloremia, alkalosis; increased BUN (especially in patients with renal insufficiency). Combined Poisoning: Signs and symptoms may be aggravated or modified by concomitant intake of antihypertensive medication, barbiturates, curare, digitalis (hypokalemia), corticosteroids, narcotics, or alcohol. Treatment There is no specific antidote. The gastric contents should be evacuated, taking adequate precautions against aspiration and for protection of the airway. An activated charcoal slurry may be instilled if conditions permit. Dialysis may not be effective for elimination of hydralazine HCI and hydrochlorothiazide because of its plasma protein binding (see CLINICAL PHARMACOLOGY). These manipulations may have to be omitted or carried out after cardiovascular status has been stabilized, since they might precipitate cardiac arrhythmias or increase the depth of shock. Support of the cardiovascular system is of primary importance in suspected hydralazine overdosage. Shock should be treated with plasma expanders. The patient's legs should be kept raised and lost fluid and electrolytes (potassium, sodium) should be replaced. If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac arrhythmia. Tachycardia responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and supported as required.

Source: http://www.rxlist.com

Hydralazine HCI and hydrochlorothiazide are supplied as two piece hard gelatin capsules, in three dosage strengths:
    25 mg hydralazine hydrochloride and 25 mg hydrochlorothiazide capsules are white and imprinted "Par 143", and are available in bottles of 100 (NDC #49884-1 43-01) 500 (NDC #49884-1 43-05) and 1000 (NDC X49884-1 43-10). 50 mg hydralazine hydrochloride and 50 mg hydrochlorothiazide capsules are white/black and imprinted "Par 144", and are available in bottles of 100 (NDC X49884-144-01), 500 (NDC X49884-144-05) and 1000 (NDC #49884-144-10). 100 mg hydralazine hydrochloride and 50 mg hydrochlorothiazide capsules are powder blue/light blue and imprinted "Par 145", and are available in bottles of 100 (NDC #49884-1 45-01), 500 (NDC #49884-145-05) and 1000 (NDC #49884-145-10).
Store at controlled room temperature 15°-30° C (59°-86° F). Dispense in a tight, light-resistant container as defined in the USP. CAUTION: Federal law prohibits dispensing without prescription.Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Included as part of the WARNINGS section. Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Senior Healthcare Matters an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Apresazide. Find what medications you are taking today.